Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 18/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106494 | 0.91 | PTGDR2 (1.00) | PTGDR2HPGD | |
| SCHEMBL5472266 | 0.89 | PTGDR2 (0.80) | PTGDR2HPGDKDM4EALDH1A1 | |
| SCHEMBL5476953 | 0.87 | KDM4E (0.83) | PTGDR2HPGDKDM4EALDH1A1 | |
| SCHEMBL5471796 | 0.87 | PTGDR2 (0.76) | PTGDR2HPGDKDM4EALDH1A1 | |
| SCHEMBL5120483 | 0.84 | PTGDR2 (1.00) | PTGDR2HPGDCYP3A4CYP2C9 | |
| SCHEMBL5480255 | 0.83 | PTGDR2 (0.70) | PTGDR2KDM4EALDH1A1 | |
| SCHEMBL5109409 | 0.82 | PTGDR2 (1.00) | PTGDR2 | |
| SCHEMBL5121458 | 0.82 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5115376 | 0.82 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5120815 | 0.81 | PTGDR2 (0.78) | PTGDR2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275995-A1 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED | 2007-11-29 | — | — | US | disclosed |
| US-7268145-B2 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20060040976-A1 | Thiobenzimidazole derivatives | TEIJIN LIMITED | 2006-02-23 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| EP-1097926-A1 | THIOBENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275995-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | PTGDR2 2748/4885HPGD 1548/4885KDM4E 3359/4885 |
| US-20060040976-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | PTGDR2 2748/4885HPGD 1548/4885KDM4E 3359/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | PTGDR2 3468/4885HPGD 1568/4885KDM4E 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.